Consortium backs €38.75m series-B for Tissium

Also joining the round were BNP Paribas Développement, the European Investment Fund, M&L Investments, ValQuest Partners, BPI France, CM-CIC Innovation, CapDecisif Management, Omnes Capital and Sofinnova Partners.

The funding will be used to support Tissium's product development and the use of its polymers across a variety of fields, including nerve repair, cardiovascular and gastroenterology. While the company has remained headquartered in Paris, the fresh capital will help the business to keep expanding in the US, given that Tissium recently opened a Boston affiliate office.

Previous funding
Omnes, CM-CIC and CapDecisif backed the company's €8m series-A round in late 2013. Tissium then raised a €22.5m extension to its series-A round three years later. Backin the business were Sofinnova Partners, which led the round, as well as BPI France and previous investors Omnes Capital, CM-­CIC Innovation and CapDecisif Management.  

Company
Founded in 2013 and based in Paris, Tissium develops proprietary technology around synthetic, biomorphic and programmable polymers. These polymers are designed to be used inside the body as sealants, adhesives, barriers, plugs or as a vehicle for drug delivery, as well as implantable devices created outside of the body using 3D printing technology.

People
Tissium – Christophe Bancel (CEO); Jay Watkins (chairman).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• BNP Paribas Développement
• Sofinnova
• BPI France
• Credit Mutuel Equity (ex CM-CIC Investissement)
• Omnes Capital
• Venture